As per Crohn’s & Colitis Foundation, Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine.
Crohn’s disease is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to Chronic abdominal pain, diarrhea, obstruction and/or perianal lesions.
In Crohn’s disease, the immune system mistakenly attacks healthy bacteria in the GI tract. Chronic inflammation causes thickening of the intestinal wall, which triggers the symptoms. Several factors have been implicated in causing Crohn’s disease, including a dysregulated immune system, an altered microbiota, genetic susceptibility, and environmental factors, but its cause is unknown. Between 5% and 20% of people who have an IBD have a first-degree relative with one. The risk is higher in Crohn’s than ulcerative colitis, and higher when both parents are affected (as per Crohn’s & Colitis Foundation of America) Crohn’s disease is more frequent in women than men, as estimated by the Centers for Disease Control and Prevention.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/crohns-disease-cd-market
The Crohn’s Disease market report covers emerging drugs, current treatment practices, Crohn’s Disease market share of the individual therapies, current and forecasted Crohn’s Disease Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Crohn’s Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Crohn’s Disease Market Key Facts
According to a study by Adcock et al., (2016), In the UK, it is estimated that at least 115,000 people have Crohn’s disease.
The disease can occur at any age and is more prevalent among adolescents and young adults between the ages of 15 and 35.
According to a study conducted by Galeone et al., (2019), in Italy, the area of Casteltermini in Sicily had one of the highest prevalence ratios of CD (322/100,000) reported worldwide.
Studies have demonstrated that the incidence rates and prevalence rates for Crohn’s disease have increased since the mid-1970s. Its prevalence has continually increased over the past 50 years, with the highest incidence being reported in northern Europe, the United Kingdom, and North America.
Key Benefits of Crohn’s Disease Market Report
-
Crohn’s Disease market report provides an in-depth analysis of Crohn’s Disease Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Crohn’s Disease market report will help in developing business strategies by understanding the Crohn’s Disease Market trends & developments, key players and future market competition that will shape and drive the Crohn’s Disease market in the upcoming years.
-
The Crohn’s Disease market report covers Crohn’s Disease current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Crohn’s Disease market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Crohn’s Disease market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Crohn’s Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Crohn’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Extensive research and development activities of pharmaceutical companies for developing therapies for Crohn’s disease and rising prevalent population, changing lifestyles, rising in smoking will further fuel the growth of the market.
Crohn’s Disease Epidemiology
The Crohn’s Disease epidemiology section covers insights about historical and current Crohn’s Disease patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Crohn’s Disease Drugs Uptake and Key Market Players
The Crohn’s Disease Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched in the market during the study period. The analysis covers Crohn’s Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Crohn’s Disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2030. Companies across the globe are working toward the development of new treatment therapies for Crohn’s disease rigorously. Some of the Key players in the Crohn’s Disease market includes:
UCB
Abbvie
Genetech
Gilead Sciences
Celgene Corporation
Millennium Pharmaceuticals
And many others
Drugs Covered
Filgotinib
Risankizumab
Etrolizumab
PDA-001
And many other
Table of Content
1. Key Insights
2. Executive Summary
3. Crohn’s Disease Competitive Intelligence Analysis
4. Crohn’s Disease Market Overview at a Glance
5. Crohn’s Disease Disease Background and Overview
6. Crohn’s Disease Patient Journey
7. Crohn’s Disease Epidemiology and Patient Population
8. Crohn’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Crohn’s Disease Unmet Needs
10. Key Endpoints of Crohn’s Disease Treatment
11. Crohn’s Disease Marketed Products
12. Crohn’s Disease Emerging Therapies
13. Crohn’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Crohn’s Disease Market Outlook (7 major markets)
16. Crohn’s Disease Access and Reimbursement Overview
17. KOL Views on the Crohn’s Disease Market.
18. Crohn’s Disease Market Drivers
19. Crohn’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Crohn’s Disease (CD) Epidemiology Forecast to 2030
DelveInsight’s ‘Crohn’s Disease (CD) Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Crohn’s Disease (CD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Crohn’s Disease (CD) Pipeline Insights, 2020
Crohn’s Disease (CD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Crohn’s Disease (CD) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/